Keyphrases
United States
100%
Systemic Therapy
100%
Line of Therapy
100%
Recurrent Endometrial Cancer
100%
Real-world Outcomes
100%
Real-world Utilization
100%
Chemotherapy
40%
Median Time
40%
Programmed Death-ligand 1 (PD-L1)
40%
Time to Next Treatment
40%
Anti-programs
40%
Adult Patients
20%
Follow-up Time
20%
Clinical Practice
20%
Therapy Initiation
20%
Treatment Choice
20%
Retrospective Observational Study
20%
Platinum-based Chemotherapy
20%
Utilization Pattern
20%
Treatment Type
20%
Treatment Line
20%
Optum
20%
Platinum Therapy
20%
Number of Treatment
20%
New Drug Approval
20%
Platinum-based
20%
Antineoplastic Drugs
20%
Utilization Outcomes
20%
Population Median
20%
Date of Death
20%
De-identified Data
20%
Therapy Utilization
20%
Treatment Sequence
20%
Non-platinum
20%
Data Mart
20%
Pharmacology, Toxicology and Pharmaceutical Science
Endometrium Cancer
100%
Chemotherapy
75%
Immunotherapy
75%
Observational Study
25%
Drug Approval
25%
Medicine and Dentistry
Systemic Therapy
100%
Uterine Cancer
100%
Immunotherapy
75%
Observational Study
25%